Ultragenyx Pharmaceutical Inc at Barclays Global Healthcare Conference Transcript
Good morning, everyone. My name is Gena Wang, I'm [a biotech] analyst from Barclays.
It is my great pleasure to introduce our first speaker, Tom Kassberg, Chief Business Officer of Ultragenyx.
Thanks, Gena. Let me see -- figure out the slides. So I'm Tom Kassberg, Chief Business Officer of Ultragenyx, and I'm pleased to be here to talk to you about Ultragenyx today.
So standard legal warning for the presentation to follow. So Ultragenyx, for some of you, I'll give you a quick introduction, was founded in 2010, went IPO in 2014. And it's an -- we talk about as a company that was built rare by design. So from the beginning, developed as a specialist rare disease company. We have -- in terms of -- we forged many new approaches and with multiple modalities that we currently employ to address these rare diseases. About 1.5 years ago, we added a gene therapy platform, which is now an
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
